Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ABT 
Abbott Laboratories (ABT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ABT (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
28 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $142.48
1 Year Target Price $142.48
| 12 | Strong Buy |
| 7 | Buy |
| 9 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.05% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 231.06B USD | Price to earnings Ratio 16.66 | 1Y Target Price 142.48 |
Price to earnings Ratio 16.66 | 1Y Target Price 142.48 | ||
Volume (30-day avg) 28 | Beta 0.69 | 52 Weeks Range 109.57 - 139.95 | Updated Date 09/16/2025 |
52 Weeks Range 109.57 - 139.95 | Updated Date 09/16/2025 | ||
Dividends yield (FY) 1.77% | Basic EPS (TTM) 7.97 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 32.43% | Operating Margin (TTM) 19.73% |
Management Effectiveness
Return on Assets (TTM) 6.62% | Return on Equity (TTM) 30.93% |
Valuation
Trailing PE 16.66 | Forward PE 23.09 | Enterprise Value 234729482308 | Price to Sales(TTM) 5.36 |
Enterprise Value 234729482308 | Price to Sales(TTM) 5.36 | ||
Enterprise Value to Revenue 5.45 | Enterprise Value to EBITDA 20.29 | Shares Outstanding 1740460032 | Shares Floating 1730225115 |
Shares Outstanding 1740460032 | Shares Floating 1730225115 | ||
Percent Insiders 0.54 | Percent Institutions 80.78 |
Upturn AI SWOT
Abbott Laboratories
Company Overview
History and Background
Abbott Laboratories was founded in 1888 by Wallace Calvin Abbott. Initially a small pharmacy, it has evolved into a global healthcare leader through innovation and strategic acquisitions.
Core Business Areas
- Established Pharmaceutical Products: Focuses on branded generic pharmaceuticals outside the United States.
- Diagnostics: Develops and manufactures diagnostic systems and tests for hospitals, labs, and point-of-care settings.
- Medical Devices: Offers medical devices for cardiovascular, neuromodulation, and diabetes care.
- Nutrition: Provides a range of nutritional products for infants, children, and adults.
Leadership and Structure
Abbott Laboratories is led by CEO Robert B. Ford. The company has a functional organizational structure with global operations managed through various divisions.
Top Products and Market Share
Key Offerings
- FreeStyle Libre: A continuous glucose monitoring (CGM) system for people with diabetes. Abbott has a significant market share in the CGM market, competing with Dexcom and Medtronic. Revenue is in the billions annually.
- Similac: Infant formula brand. Competitors include Nestle's Gerber and Mead Johnson Nutrition's Enfamil. Abbott holds a substantial share of the infant formula market.
- Ensure: Adult nutritional beverage. Competitors include Nestle's Boost and other private label brands. Abbott holds a leading share of the adult nutrition market.
- Alinity: Family of diagnostic systems for clinical chemistry, immunoassay, blood screening, and point-of-care testing. Competitors include Roche, Siemens Healthineers, and Beckman Coulter.
Market Dynamics
Industry Overview
The healthcare industry is characterized by increasing demand, technological advancements, and regulatory pressures. Aging populations and rising chronic diseases are driving growth.
Positioning
Abbott is a diversified healthcare company with a strong global presence and a focus on innovation. Its competitive advantages include a broad product portfolio, established brands, and robust R&D capabilities.
Total Addressable Market (TAM)
The global healthcare market is valued in the trillions of dollars. Abbott's diverse product portfolio allows it to address significant portions of this TAM, estimated to be hundreds of billions, positioning it as a market leader in many segments.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Global presence
- Strong R&D capabilities
- Established brands
- Robust financial performance
Weaknesses
- Exposure to regulatory risks
- Dependence on key products
- Competitive pricing pressure
- Supply chain vulnerabilities
Opportunities
- Expanding into emerging markets
- Developing new technologies
- Acquiring complementary businesses
- Capitalizing on aging populations
Threats
- Increased competition
- Patent expirations
- Economic downturns
- Changes in healthcare policies
- Disruptive technologies
Competitors and Market Share
Key Competitors
- JNJ
- DHR
- BSX
- MDT
- ROCHE (OTC)
Competitive Landscape
Abbott competes with a variety of companies in different segments of the healthcare industry. Its diversified product portfolio and global presence provide a competitive advantage.
Major Acquisitions
St. Jude Medical
- Year: 2017
- Acquisition Price (USD millions): 25000
- Strategic Rationale: Expanded Abbott's cardiovascular and neuromodulation portfolio.
Alere
- Year: 2017
- Acquisition Price (USD millions): 5300
- Strategic Rationale: Strengthened Abbott's diagnostics business.
Growth Trajectory and Initiatives
Historical Growth: Abbott has demonstrated consistent growth through organic expansion and strategic acquisitions.
Future Projections: Analysts project continued growth for Abbott, driven by its strong product portfolio and global expansion. Revenue is expected to grow in the mid-single digits annually.
Recent Initiatives: Abbott has recently focused on expanding its diagnostics business and investing in new technologies, such as continuous glucose monitoring.
Summary
Abbott Laboratories is a strong, diversified healthcare company with a solid track record of growth and innovation. Its diverse portfolio allows it to navigate market conditions effectively. Abbott must watch out for increased competition and regulatory changes impacting the healthcare sector while capitalizing on growth in emerging markets. Its strong financials and dividend history make it a desirable investment option.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Abbott Laboratories Investor Relations
- SEC Filings (10-K, 10-Q)
- Market Research Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abbott Laboratories
Exchange NYSE | Headquaters North Chicago, IL, United States | ||
IPO Launch date 1978-01-13 | Chairman of the Board, President & CEO Mr. Robert B. Ford | ||
Sector Healthcare | Industry Medical Devices | Full time employees 114000 | Website https://www.abbott.com |
Full time employees 114000 | Website https://www.abbott.com | ||
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.